BTIG Cuts Abbott Laboratories (ABT) Price Target to $125
Key Points
- On October 22, 2026, BTIG maintained its Buy rating on Abbott Laboratories while reducing its price target to $125.00 from $134.00.
- BTIG's $125 price target implies 23.35% upside from Abbott Laboratories's ($ABT) current $101.34 share price.
- Abbott Laboratories recently traded around $100.56, sitting below its 50-day moving average of $105.49 and its 52-week high of $132.03.
- The medical device maker posts trailing twelve-month revenue of $46.58 billion with earnings of $2.69 per share.
Get Abbott Laboratories text alerts
We text you when insiders, Congress, analysts or big funds move on $ABT.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
On October 22, 2026, research firm BTIG maintained its Buy rating on Abbott Laboratories (NYSE: ABT) while lowering its price target from $134.00 to $125.00. The update arrived in a research note from the firm as analysts continue to review health care sector valuations.
ABT
Abbott Laboratories
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
BTIG's Call on Abbott Laboratories
BTIG kept a positive outlook on the medical device maker with its Buy rating, though the reduced target reflects a more cautious stance on near-term upside. The stock closed at $100.51 on October 21, 2026, and recently traded at $100.56.
Other Institutional Activity in Abbott Laboratories
Large investors continue to shift positions in the medical products firm. Global Strategic Investment Solutions added 2,291 shares to end with 2,291 shares worth about $226,402. Elser Financial Planning picked up 2,209 shares, finishing with 2,209 shares valued at roughly $218,315. Y-Intercept grew its holdings by 250,717 shares to hold 250,717 shares worth about $24.78 million. Meanwhile, Capital International Investors cut its stake by 2,842,222 shares, or 7.6%, ending with 34,654,113 shares valued at approximately $3.48 billion.
Abbott Laboratories Stock Down 1.1%
Abbott Laboratories shares recently changed hands around $100.56, remaining near the lower end of their 52-week range between $81.97 and $132.03. The price sits below both the 50-day moving average of $105.49 and the 200-day moving average of $102.46. The recent quote lands roughly 16.5% below the average analyst price target of $120.41.
$ABT price target
Abbott Laboratories daily closes and this analyst's $125 target. Not advice.
Recent Earnings
Abbott Laboratories posts trailing twelve-month revenue of $46.58 billion with earnings of $2.69 per share.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Investors receive an annual dividend of $2.52 per share, giving the stock a dividend yield of 2.46%.
Insider Buying and Selling at Abbott Laboratories
Insiders executed several transactions in recent months, including a purchase of 2,000 shares by Director John G. Stratton for $173,640 on May 7, 2026. Officer Louis H Morrone sold 5,850 shares for $642,506 on August 11, 2026. CEO Robert B. Ford disposed of 398,832 shares valued at $46,204,798 on August 25, 2026, and Officer John A. Mccoy Jr sold 27 shares for $2,958 on September 2, 2026.
Analysts Set New Price Targets
Wall Street firms updated their outlooks ahead of BTIG's move. Rothschild & Co upgraded the stock to a Buy with a $127 target on October 2, 2026. Barclays initiated coverage with an Overweight rating and a $120 target on October 7, 2026. TD Cowen reiterated a Buy rating with a $135 target on October 16, 2026. On the same day as BTIG's note, Baird maintained an Outperform rating while raising its target from $121 to $123. Overall, the stock holds a consensus recommendation of strong buy across 26 analysts.
About Abbott Laboratories
Headquartered in Abbott Park, Illinois, Abbott Laboratories creates and distributes health care products around the globe. The enterprise operates across four main divisions: established pharmaceutical items, diagnostic tools, nutritional goods, and medical devices.
Bottom Line
Investors will watch how health care demand tracks against broader market trends as upcoming earnings reports approach. The recent adjustments by BTIG and peer institutions highlight active repositioning across major medical device holdings.
Related Filing Alerts
Source: BTIG's rating change on $ABT (Oct 22, 2026). Written by software, not financial advice. How we make alerts